130 related articles for article (PubMed ID: 38372045)
1. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
Cerbone L; Delfanti S; Crivellari S; De Angelis AM; Mazzeo L; Proto C; Occhipinti M; Lo Russo G; Dellepiane C; Biello F; Alabiso I; Verderame F; Gauna R; De Simone I; Cuppone F; Petraglia S; Pasello G; Ceresoli GL; Garassino MC; Torri V; Grosso F
Tumori; 2024 Jun; 110(3):168-173. PubMed ID: 38372045
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA; Ewings S; Ottensmeier C; Califano R; Hanna GG; Hill K; Danson S; Steele N; Nye M; Johnson L; Lord J; Middleton C; Szlosarek P; Chan S; Gaba A; Darlison L; Wells-Jordan P; Richards C; Poile C; Lester JF; Griffiths G;
Lancet Oncol; 2021 Nov; 22(11):1530-1540. PubMed ID: 34656227
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
4. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.
Fennell DA; Kirkpatrick E; Cozens K; Nye M; Lester J; Hanna G; Steele N; Szlosarek P; Danson S; Lord J; Ottensmeier C; Barnes D; Hill S; Kalevras M; Maishman T; Griffiths G
Trials; 2018 Apr; 19(1):233. PubMed ID: 29669604
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
McNamee N; Harvey C; Gray L; Khoo T; Lingam L; Zhang B; Nindra U; Yip PY; Pal A; Clay T; Arulananda S; Itchins M; Pavlakis N; Kao S; Bowyer S; Chin V; Warburton L; Pires da Silva I; John T; Solomon B; Alexander M; Nagrial A
J Thorac Oncol; 2024 Apr; 19(4):636-642. PubMed ID: 38036250
[TBL] [Abstract][Full Text] [Related]
9. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.
Yoneda H; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Ogino H; Otsuka K; Nishioka Y
BMC Pulm Med; 2021 Nov; 21(1):373. PubMed ID: 34781910
[TBL] [Abstract][Full Text] [Related]
10. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Laune Q; Brosseau S
Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
[TBL] [Abstract][Full Text] [Related]
12. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
14. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
Nakamura A; Kondo N; Nakamichi T; Kuroda A; Hashimoto M; Matsumoto S; Yokoi T; Kuribayashi K; Kijima T; Hasegawa S
Jpn J Clin Oncol; 2020 Aug; 50(8):920-925. PubMed ID: 32463095
[TBL] [Abstract][Full Text] [Related]
15. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
Kim RY; Li Y; Marmarelis ME; Vachani A
Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
18. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Uprety D
Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
[No Abstract] [Full Text] [Related]
19. Clinical Efficacy and Safety of Nivolumab in Malignant Non-Pleural Mesothelioma: A Multicenter, Open-Label, Single-Arm, Japanese Phase II Trial (Viola) Protocol.
Kuribayashi K; Igeta M; Daimon T; Ibu M; Suna S; Okamoto R; Kijima T
Oncology; 2023; 101(4):257-261. PubMed ID: 36566745
[TBL] [Abstract][Full Text] [Related]
20. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
